Navigation Links
Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
Date:9/30/2009

VIENNA, Sept. 30 /PRNewswire/ -- Intarcia Therapeutics, Inc. today presented final results from its Phase 1b clinical study of ITCA 650 (DUROS® continuous delivery of exenatide) for the treatment of type 2 diabetes at the Annual Conference of the European Association for the Study of Diabetes in Vienna, Austria. Results of the study demonstrate substantial reductions in fasting plasma glucose (FPG) within 24 hours of the start of treatment and a sustained glucose lowering effect throughout the 28 day treatment period. Other important results from the study were significant reductions in postprandial glucose (PPG), HbA1c and body weight.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO)

"The results from the ITCA 650 phase 1b study demonstrate the potential for DUROS continuous delivery of exenatide to improve the treatment of type 2 diabetes," said Kenneth L. Luskey, MD, VP Clinical Research at Intarcia. "ITCA 650 addresses some of the key limitations observed with other incretin mimetic therapies by eliminating the need for frequent self-injection, limiting the incidence and persistence of nausea and ensuring treatment compliance."

The phase 1b dose ranging study was conducted at multiple centers in the United States and evaluated a 28-day course of ITCA 650 treatment among patients with type 2 diabetes (10-12 patients/dose arm) on a stable treatment regimen of diet and exercise or treatment with metformin and/or thiazolidinediones. The study included 4 dose arms to which patients were randomized to receive 10 mcg/day, 20mcg/day, 40 mcg/day or 80 mcg/day exenatide for a 28 day treatment duration via a single insertion of ITCA 650. ITCA 650 therapy in this phase 1b trial was administered for the full course of treatment with a single insertion of the I
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
2. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
5. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
6. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
7. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
8. Nile Therapeutics, Inc. Adds to Executive Management Team
9. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
10. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
11. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014  PAREXEL International Corporation (NASDAQ: ... presenting at the Baird Healthcare Conference in New York.  ... Financial Officer, will be making a presentation on PAREXEL ... Wednesday, Sept. 3, 2014. A live webcast ... section of PAREXEL,s website at www.PAREXEL.com in ...
(Date:8/20/2014)... Canada (PRWEB) August 20, 2014 Not ... that E&L studies should be performed late in the ... is known. But current regulatory trends suggest that, like ... on the rise. In recent years, multiple drug sponsors ... packages or address specific questions during phase I/II. It’s ...
(Date:8/20/2014)... nerves in your ear could improve the health of ... the University of Leeds used a standard TENS machine ... electrical pulses to the tragus, the small raised flap ... of the ear canal. , The stimulation changed the ... reducing the nervous signals that can drive failing hearts ...
(Date:8/20/2014)... August 20, 2014 GraphDB™ ... today including improvements to the enterprise replication cluster, ... for Lucene, SOLR and Elasticsearch. This release happens ... high performance triplestore – GraphDB™ was formerly known ... deploying the only mature enterprise resilient RDF triplestore ...
Breaking Biology Technology:PAREXEL International To Present At Baird Healthcare Conference 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2'Tickling' your ear could be good for your heart 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4
... RICHMOND, Virginia, ROSH HA,AYIN, Israel, June 16 ,EnzySurge ... advanced,chronic wound management, recently announced the formation of ... and practitioners with diversified expertise in chronic wounds.,The ... MD, PhD, Diane L.,Krasner, PhD RN, FAAN, Joseph ...
... June 16 Alexandria Real Estate,Equities, Inc. (NYSE: ... 100 life science,executives from around the world on ... environmentally sustainable operations in the San Diego life,science ... being held in,conjunction with the Biotechnology Industry Organization,s ...
... data management product for the, hospital ... connection, BOTHELL, Wash., June 16 Cardiac ... flagship HeartCentrix(R) data,management product for the hospital market. ... across all facilities within a,hospital network. Cardiac Science ...
Cached Biology Technology:EnzySurge, Maker of DermaStream(TM), Announces the Formation of its Scientific Advisory Board 2EnzySurge, Maker of DermaStream(TM), Announces the Formation of its Scientific Advisory Board 3EnzySurge, Maker of DermaStream(TM), Announces the Formation of its Scientific Advisory Board 4Alexandria Real Estate Equities, Inc. Features Green Buildings and Sustainable Operations Initiatives and Tour at 2008 BIO 2Alexandria Real Estate Equities, Inc. Features Green Buildings and Sustainable Operations Initiatives and Tour at 2008 BIO 3Alexandria Real Estate Equities, Inc. Features Green Buildings and Sustainable Operations Initiatives and Tour at 2008 BIO 4Cardiac Science Launches 'Anywhere' Data Management for HIS and EMR Systems 2Cardiac Science Launches 'Anywhere' Data Management for HIS and EMR Systems 3Cardiac Science Launches 'Anywhere' Data Management for HIS and EMR Systems 4
(Date:8/20/2014)... screening outcomes of approximately 3 million infants, a team ... the University of Massachusetts Medical School, have shown that ... successfully implemented across public health newborn screening programs. Data ... 20 issue of the Journal of the American ... of SCID in newborns is higher than previously thought ...
(Date:8/20/2014)... has awarded the Oklahoma Medical Research Foundation a five-year, ... and the bacteria,s effects on humans. , For ... colleagues have studied the human immune response to anthrax ... Immunology. The original funding came soon after anthrax-laced letters ... the terrorist attacks of Sept. 11, 2001. , ...
(Date:8/20/2014)... EUGENE, Ore. -- When are athletes who have suffered ... of Oregon study has found that high school athletes ... within 60 days experience a significant regression in their ... , The regression, as seen in changes in their ... of 19 athletes. Ten of the 12 had returned ...
Breaking Biology News(10 mins):Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3$14.5 million grant awarded to continue anthrax studies 2Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... effects of antioxidants such as vitamin C. Scientists at ... of lipid the ability of antioxidants, such as ascorbic ... against the generation of potential cancer-forming compounds in the ... “Our results illustrate how diet can influence gastric biochemistry? ...
... differs from other individuals, the level at which those ... person to another, scientists have learned. And though some ... different populations ?Asians versus Europeans, for instance ?more of ... the biological meaning of "race." , The findings ...
... Al Gore's film, An Inconvenient Truth, has generated greater ... the more rapid warming that has occurred within major ... 10 degrees hotter than their surroundings. These metropolitan hot ... can stress the animals and plants that make their ...
Cached Biology News:Individuals and populations differ in gene activity levels, not just genes 2City ants take the heat 2
... MultiScribe Reverse Transcriptase is a recombinant ... transcriptase. MultiScribe Reverse Transcriptase is similar ... in its recommended usage. MuLV reverse ... polymerase that uses single-stranded RNA as ...
... determination of digitonin and digoxin. Physical form: Lyophilized ... and 0.06% NaCl Preparation Note: Sodium iodide ... Res. Commun., 19, 755 (1965). Unit Definition: ... phosphorus from ATP per min at pH 7.4 ...
... protease from human rhinovirus (HRV 3C) is ... line of restriction grade proteases. The recombinant ... protein, which recognizes the same cleavage site ... 22 KDa size of the protease, optimal ...
... IEC Centra CL3 series is designed ... research and clinical applications at a ... package includes quick connect rotors and ... yet intuitive interface allows you to ...
Biology Products: